Leading Chinese drugmakers, such as Jiangsu Hengrui Pharmaceuticals and CanSino Biologics, are struggling to recruit internationally experienced staff needed to develop and commercialize promising medicines overseas, according to industry executives.
Global Ambitions
China’s rapid rise as a hub for testing experimental, next-generation medicines is outpacing the industry’s ability to build the workforce needed to take those products global. Chinese drugmakers are expanding overseas as regulators seek clinical data from more diverse patient populations.
Sun Piaoyang, chairman of oncology and metabolic disease specialist Hengrui, said his company’s global multi-center clinical trial, overseas registration, and commercialization efforts require more highly qualified professionals, yet the industry faces a shortage of people with global development, international regulatory, and cross-cultural management expertise.
Yu Xuefeng, CEO of vaccine maker CanSino, said qualified specialists remained scarce in areas such as conducting overseas clinical trials, preparing regulatory submissions for multiple jurisdictions, and international marketing.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
